Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Withdrawn 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 5INDUSTRY 3OTHER_GOV 2

Study Type

Interventional 3

Sponsor

Cancer Type

Other 3

Conditions

Mucositis 27Opioid-Induced Constipation 20Constipation 18Head and Neck Neoplasms 14Stomatitis 13Pain 12Neoplasms 7Obesity 6Intestinal Diseases 5Bronchiolitis Obliterans Syndrome 5Oral Ulcer 3Lymphoma, Follicular 3Hematologic Neoplasms 3Chemotherapy-induced Peripheral Neuropathy 3Breast Neoplasms 3Xerostomia 2Venous Thromboembolism 2Tumor Lysis Syndrome 2Thrombocytopenia 2Teratogenesis 2Sexual Dysfunctions, Psychological 2Sexual Dysfunction, Physiological 2Renal Insufficiency 2Prostatic Neoplasms 2Peripheral Nervous System Diseases 2Overweight 2Obesity, Morbid 2Neutropenia 2Myocardial Infarction 2Myelodysplastic Syndromes 2

Interventions

ART123 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Chemotherapy-induced Peripheral Neuropathy × Other × Clear all
NCT05251727 2024-08-19

Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients

Veloxis Pharmaceuticals

Phase 1 Terminated
77 enrolled
Other

Chemotherapy-induced Peripheral Neuropathy

NCT05593614 2024-07-16

ACT

AlgoTherapeutix

Phase 2 Active not recruiting
276 enrolled
Other

Chemotherapy-induced Peripheral Neuropathy

NCT04282590 2022-03-15

A Study to Investigate the Safety and Efficacy of TRK-750 for the Treatment of Patients With CIPN (Chopin Study)

Toray Industries, Inc

Phase 2 Withdrawn
Other

Chemotherapy-induced Peripheral Neuropathy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡